Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence

被引:52
作者
Masuda, Daisaku [1 ]
Sugimoto, Taizo [2 ]
Tsujii, Ken-ichi [3 ]
Inagaki, Miwako [1 ]
Nakatani, Kazuhiro [1 ]
Yuasa-Kawase, Miyako [1 ]
Tsubakio-Yamamoto, Kazumi [1 ]
Ohama, Tohru [1 ,4 ]
Nishida, Makoto [1 ,4 ]
Ishigami, Masato [1 ,5 ]
Kawamoto, Toshiharu [6 ]
Matsuyama, Akifumi [7 ]
Sakai, Naohiko [8 ]
Komuro, Issei [1 ]
Yamashita, Shizuya [1 ]
机构
[1] Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, Suita, Osaka 5650871, Japan
[2] Sugimoto Clin, Suita, Osaka, Japan
[3] Tsujii Clin, Suita, Osaka, Japan
[4] Osaka Univ, Hlth Care Ctr, Osaka, Japan
[5] Osaka Univ, Dept Biomed Informat, Grad Sch Med, Div Hlth Sci, Suita, Osaka 5650871, Japan
[6] Natl Hosp Org, Kure Med Ctr, Kure Heart Ctr, Kure, Hiroshima, Japan
[7] Fdn Biomed Res & Innovat, Dept Somat Stem Cell Therapy, Inst Biomed Res & Innovat, Kobe, Hyogo, Japan
[8] Sakai Clin, Moriguchi, Osaka, Japan
关键词
Apolipoprotein B-48; chylomicrons; coronary artery disease; postprandial hyperlipidemia; remnant lipoproteins; RICH LIPOPROTEIN METABOLISM; POSTPRANDIAL HYPERLIPIDEMIA; REMNANT LIPOPROTEINS; CHYLOMICRON REMNANTS; ASSOCIATION; HYPERTRIGLYCERIDEMIA; ATHEROSCLEROSIS; ATHEROGENESIS; ATORVASTATIN; PARTICLES;
D O I
10.1111/j.1365-2362.2012.02687.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Eur J Clin Invest 2012; 42 (9): 992999 Abstract Background Postprandial hyperlipidemia partially refers to the postprandial accumulation of chylomicrons and chylomicron remnants (CM-R). Many in vitro studies have shown that CM-R has highly atherogenic properties, but consensus is lacking on whether CM-R accumulation correlates with the development of atherosclerotic cardiovascular diseases. We investigated the correlation between CM-R accumulation and the prevalence of coronary artery disease (CAD). Design Subjects who received a coronary angiography and did not take any lipid-lowering drugs (n = 189) were enrolled. Subjects with coronary artery stenosis (= 75%) were diagnosed as CAD. Biochemical markers for glucose and lipid metabolism including fasting apolipoprotein (apo) B-48 concentration were compared between CAD patients (n = 96) and age-, sex-, and body mass index (BMI)-matched non-CAD subjects without overt coronary stenosis (< 75%) (n = 67). We tried to determine which metabolic parameters were correlated with the prevalence of CAD by multiple logistic regression analysis, and whether or not the combination of high apo B-48 and other coronary risk factors (high triglyceride, low HDL-C, high HbA1c or low adiponectin levels) increased the prevalence of CAD. Results Fasting serum apo B-48 levels were significantly higher in CAD patients than in non-CAD subjects (3.9 +/- 2.4 vs. 6.9 +/- 2.6 mu g/mL, P < 0.0001) and had the most significant correlation with the existence of CAD. The clustering of high fasting apo B-48 levels (> 4.34 mu g/mL, the cut-off value) and other coronary risk factors were found to be associated with a stronger risk of CAD compared with single high fasting apo B-48 levels. Conclusion Fasting serum apo B-48 levels significantly correlated with the prevalence of CAD.
引用
收藏
页码:992 / 999
页数:8
相关论文
共 30 条
[1]  
[Anonymous], 2005, J JPN SOC INT MED, DOI [DOI 10.5551/JAT.12.301, 10.5551/jat.12.301]
[2]   Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome [J].
Chan, D. C. ;
Watts, G. F. ;
Ng, T. W. K. ;
Yamashita, S. ;
Barrett, P. H. R. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 (10) :743-751
[3]   Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism [J].
Chan, DC ;
Watts, GF ;
Ng, TWK ;
Uchida, Y ;
Sakai, N ;
Yamashita, S ;
Barrett, PHR .
CLINICAL CHEMISTRY, 2005, 51 (03) :578-585
[4]  
Fujioka Y, 1998, J LIPID RES, V39, P2339
[5]   Remnant Lipoproteins As Strong Key Particles to Atherogenesis [J].
Fujioka, Yoshio ;
Ishikawa, Yuichi .
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2009, 16 (03) :145-154
[6]   The close relationship between postprandial remnant metabolism and insulin resistance [J].
Funada, J ;
Sekiya, M ;
Otani, T ;
Watanabe, K ;
Sato, M ;
Akutsu, H .
ATHEROSCLEROSIS, 2004, 172 (01) :151-154
[7]   Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].
Grundy, SM ;
Cleeman, JI ;
Daniels, SR ;
Donato, KA ;
Eckel, RH ;
Franklin, BA ;
Gordon, DJ ;
Krauss, RM ;
Savage, PJ ;
Smith, SC ;
Spertus, JA ;
Costa, F .
CIRCULATION, 2005, 112 (17) :2735-2752
[8]   Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism [J].
Hanada, Hiroyuki ;
Mugii, Satomi ;
Okubo, Manabu ;
Maeda, Ikuhiro ;
Kuwayama, Kazuya ;
Hidaka, Yoh ;
Kitazume-Taneike, Rika ;
Yamashita, Taiji ;
Kawase, Ryota ;
Nakaoka, Hajime ;
Inagaki, Miwako ;
Yuasa-Kawase, Miyako ;
Nakatani, Kazuhiro ;
Tsubakio-Yamamoto, Kazumi ;
Masuda, Daisaku ;
Ohama, Tohru ;
Matsuyama, Akifumi ;
Ishigami, Masato ;
Nishida, Makoto ;
Komuro, Issei ;
Yamashita, Shizuya .
CLINICA CHIMICA ACTA, 2012, 413 (1-2) :160-165
[9]  
Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014
[10]   Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins [J].
Ishigami, M ;
Yamashita, S ;
Sakai, N ;
Hirano, K ;
Hiraoka, H ;
Nakamura, T ;
Matsuzawa, Y .
ATHEROSCLEROSIS, 2003, 168 (02) :359-366